Who is sponsoring NCT02063022?

NCT02063022 is sponsored by Italian Sarcoma Group.

What drugs are being tested in NCT02063022?

Interventions in NCT02063022: Standard treatment (as per protocol ISG SSG III), Intensified chemotherapy.

What condition does NCT02063022 study?

NCT02063022 studies Ewing's Sarcoma.

Is NCT02063022 still recruiting?

NCT02063022 is currently completed. Last updated 19 September 2022.

Last reviewed 2022-09-19 · How we verify

NCT02063022: EW-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

Completed Phase 3 Last updated 19 September 2022

What this trial tests

Phase 3 trial testing Standard treatment (as per protocol ISG SSG III) in Ewing's Sarcoma in 278 participants. Completed in 14 April 2022.

Timeline

22 January 2009

Primary endpoint
14 April 2022

14 April 2022

Quick facts

Lead sponsor	Italian Sarcoma Group
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	278
Start date	22 January 2009
Primary completion	14 April 2022
Estimated completion	14 April 2022
Sites	14 locations across Italy

Drugs / interventions tested

Standard treatment (as per protocol ISG SSG III) — full drug profile →
Intensified chemotherapy — full drug profile →

Conditions studied

Ewing's Sarcoma — all drugs for Ewing's Sarcoma →

Sponsor

Italian Sarcoma Group — full company profile →

Who can join

Under 40, any sex, with Ewing's Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment. Both arms will receive an induction treatment followed by surgery (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on the basis of the response to the induction treatment (good or poor)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.
Luksch R, Palmerini E, Milano GM, Paioli A, et al · · 2025 · cited 1× · PMID 39833645 · DOI 10.1002/pbc.31551

Verify or expand the search:

Other recruiting trials for Ewing's Sarcoma

Currently open trials in the same condition.

NCT04671693 — A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Sur · NA · active not recruiting
NCT03442465 — Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas · recruiting

Other Italian Sarcoma Group trials

Trials by the same sponsor.

NCT07265661 — Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma · NA · not yet recruiting
NCT07328425 — Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS · Phase 2 · recruiting
NCT06375941 — Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars · recruiting
NCT04274023 — Study on TSR-042 in Advanced Clear Cell Sarcoma · Phase 2 · terminated
NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02063022 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Italian Sarcoma Group
Last refreshed: 19 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02063022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing